<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397891</url>
  </required_header>
  <id_info>
    <org_study_id>3133K1-102</org_study_id>
    <nct_id>NCT00397891</nct_id>
  </id_info>
  <brief_title>Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational
      AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between dose of study medication and up to 52 weeks after the dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Physical Examinations</measure>
    <time_frame>Screening up to Week 52</time_frame>
    <description>Physical examination included the assessment of abdomen, back/spinal, breasts, external genitalia, extremities, general appearance, head, eyes, ears, nose, throat (HEENT), heart, lungs, lymph nodes and skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Importance</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Criteria for determining potentially clinically important (PCI) vital signs was described as: supine blood pressure (BP)- systolic (greater than or equal to [&gt;=]160 millimeter mercury [mm Hg] or less than or equal to [&lt;=]90 mm Hg and increase or decrease of &gt;=20 mm Hg compared to baseline value), supine diastolic BP (&gt;=100 mm Hg or &lt;= 50 mm Hg and increase or decrease of &gt;=15 mm Hg compared to baseline value), supine pulse rate (&gt;=120 beats per minute (bpm) or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), body temperature (&gt;38.3 degree Celsius and &lt;35 degree Celsius).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance</measure>
    <time_frame>Screening up to Week 16</time_frame>
    <description>Criteria for determining PCI ECG result was described as: heart rate (&gt;=120 bpm or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), PR interval (&gt;=220 millisecond (msec) and change of &gt;=20 msec compared to baseline value), QRS interval (&gt;=120 msec), corrected QT (QTc) interval for men (&gt;450 msec), QTc interval for women (&gt;470 msec).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Test Results of Potential Clinical Importance</measure>
    <time_frame>Week 1 up to Week 52</time_frame>
    <description>Criteria for PCI laboratory results: hematology (hematocrit [decrease &gt;=5%], hemoglobin [decrease &gt;=20gram/liter {g/L}] from baseline, white blood cells [&lt;3], neutrophils [&lt;1.5], platelet [&lt;100], eosinophils [&gt;0.5] *10^9/L); blood chemistry (sodium [&gt;5], potassium [&gt;0.5], fasting glucose [&gt;0.83], phosphorous [&gt;0.162] millimole/L [mmol/L] above upper limit of normal [ULN] and below lower limit of normal [LLN], non-fasting glucose &gt;5 mmol/L above ULN, &gt;0.56 mmol/L below LLN, creatinine &gt;1.36*ULN, blood urea nitrogen &gt;1.5*ULN, calcium [change of &gt;=0.25 mmol/L], total protein [change of &gt;=20g/L], albumin [change of &gt;=10g/L], uric acid [change of &gt;0.119mmol/L] from baseline and outside normal limits); Liver function tests (alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT] and aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] &gt;2*ULN, total bilirubin &gt;2*ULN, alkaline phosphatase &gt;1.5*ULN, gamma-glutamyl-transpeptidase [GGT] &gt;3*ULN).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Neurological Examinations</measure>
    <time_frame>Screening up to Week 52</time_frame>
    <description>Neurological examination included the assessment of mental status, cranial nerves, visual fields, sensory, motor, gait, primitive reflexes and tendon reflexes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>AUC is a measure of the serum concentration of the drug over time. AUC (0-t) is area under the serum concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>AUC is a measure of the serum concentration of the drug over time. AUC (0 - ∞) is area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>Volume of distribution is defined as the theoretical blood volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>MRT is average time for which the drug molecules resides in the body, after administration. It is calculated as area under the serum concentration versus time first moment curve from time zero (pre-dose) to extrapolated infinite time (AUMC [0 - ∞]) divided by area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (AUC[0 - ∞]). AUMC (0-∞) is calculated as AUMC(0-inf)= AUMCt + [(t x Ct) / kel] + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method, Ct is the concentration at time t and kel is the terminal phase rate constant. Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Decay Half-Life (t1/2) of Bapineuzumab</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
    <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half. Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bapineuzumab Concentrations</measure>
    <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 168, 336, 672, 1008, 1344, 1848, 2184, 2688, 4368, 8736 hours post start of infusion</time_frame>
    <description>Serum bapineuzumab concentration was determined by using a validated enzyme-linked immunosorbent assay (ELISA) method. Participants who received bapineuzumab were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Serum Anti-Bapineuzumab Antibody</measure>
    <time_frame>Baseline (Day 1) up to Week 52</time_frame>
    <description>Serum anti-bapineuzumab antibody concentration was determined by using a validated ELISA method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Amyloid-beta (x-40) Concentrations</measure>
    <time_frame>0 (pre-infusion), 1, 6, 24, 336, 1008, 2184, 2688, 4368, 8736 hours post start of infusion</time_frame>
    <description>Amyloid-beta (A-beta) is a peptide fragment of the amyloid precursor protein which is one of the characteristic hallmarks of Alzheimer's disease (AD). Total plasma amyloid-beta (x-40) was determined using a validated ELISA method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bapineuzumab 0.15 mg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bapineuzumab 0.5 mg/kg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bapineuzumab 1.0 mg/kg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bapineuzumab</intervention_name>
    <description>The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bapineuzumab</intervention_name>
    <description>The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bapineuzumab</intervention_name>
    <description>The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AD

          -  Age 50-85

          -  MMSE 14-26

          -  Other Inclusion Criteria Apply

        Exclusion Criteria:

          -  Significant Neurological Disease

          -  Major Psychiatric Disorder

          -  Clinically Significant Systemic Illness

          -  Other Exclusion Criteria Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3133K1-102&amp;StudyName=Study%20Evaluating%20Single%20Ascending%20Doses%20of%20AAB-001%20Vaccine%20SAD%20Japanese%20Patients%20With%20Alzheimers%20Disease</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <results_first_submitted>August 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2014</results_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bapineuzumab 0.15 mg/kg</title>
          <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Bapineuzumab 0.5 mg/kg</title>
          <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Bapineuzumab 1.0 mg/kg</title>
          <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Bapineuzumab 2.0 mg/kg</title>
          <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Bapineuzumab 0.15 mg/kg</title>
          <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Bapineuzumab 0.5 mg/kg</title>
          <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Bapineuzumab 1.0 mg/kg</title>
          <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Bapineuzumab 2.0 mg/kg</title>
          <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.67" spread="5.16"/>
                    <measurement group_id="B2" value="72.17" spread="8.38"/>
                    <measurement group_id="B3" value="72.17" spread="10.87"/>
                    <measurement group_id="B4" value="64.83" spread="5.19"/>
                    <measurement group_id="B5" value="68.75" spread="8.89"/>
                    <measurement group_id="B6" value="67.78" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between dose of study medication and up to 52 weeks after the dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between dose of study medication and up to 52 weeks after the dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Physical Examinations</title>
        <description>Physical examination included the assessment of abdomen, back/spinal, breasts, external genitalia, extremities, general appearance, head, eyes, ears, nose, throat (HEENT), heart, lungs, lymph nodes and skin.</description>
        <time_frame>Screening up to Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Physical Examinations</title>
          <description>Physical examination included the assessment of abdomen, back/spinal, breasts, external genitalia, extremities, general appearance, head, eyes, ears, nose, throat (HEENT), heart, lungs, lymph nodes and skin.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Importance</title>
        <description>Criteria for determining potentially clinically important (PCI) vital signs was described as: supine blood pressure (BP)- systolic (greater than or equal to [&gt;=]160 millimeter mercury [mm Hg] or less than or equal to [&lt;=]90 mm Hg and increase or decrease of &gt;=20 mm Hg compared to baseline value), supine diastolic BP (&gt;=100 mm Hg or &lt;= 50 mm Hg and increase or decrease of &gt;=15 mm Hg compared to baseline value), supine pulse rate (&gt;=120 beats per minute (bpm) or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), body temperature (&gt;38.3 degree Celsius and &lt;35 degree Celsius).</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Importance</title>
          <description>Criteria for determining potentially clinically important (PCI) vital signs was described as: supine blood pressure (BP)- systolic (greater than or equal to [&gt;=]160 millimeter mercury [mm Hg] or less than or equal to [&lt;=]90 mm Hg and increase or decrease of &gt;=20 mm Hg compared to baseline value), supine diastolic BP (&gt;=100 mm Hg or &lt;= 50 mm Hg and increase or decrease of &gt;=15 mm Hg compared to baseline value), supine pulse rate (&gt;=120 beats per minute (bpm) or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), body temperature (&gt;38.3 degree Celsius and &lt;35 degree Celsius).</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance</title>
        <description>Criteria for determining PCI ECG result was described as: heart rate (&gt;=120 bpm or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), PR interval (&gt;=220 millisecond (msec) and change of &gt;=20 msec compared to baseline value), QRS interval (&gt;=120 msec), corrected QT (QTc) interval for men (&gt;450 msec), QTc interval for women (&gt;470 msec).</description>
        <time_frame>Screening up to Week 16</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance</title>
          <description>Criteria for determining PCI ECG result was described as: heart rate (&gt;=120 bpm or &lt;=45 bpm and increase or decrease of &gt;15 bpm compared to baseline value), PR interval (&gt;=220 millisecond (msec) and change of &gt;=20 msec compared to baseline value), QRS interval (&gt;=120 msec), corrected QT (QTc) interval for men (&gt;450 msec), QTc interval for women (&gt;470 msec).</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Test Results of Potential Clinical Importance</title>
        <description>Criteria for PCI laboratory results: hematology (hematocrit [decrease &gt;=5%], hemoglobin [decrease &gt;=20gram/liter {g/L}] from baseline, white blood cells [&lt;3], neutrophils [&lt;1.5], platelet [&lt;100], eosinophils [&gt;0.5] *10^9/L); blood chemistry (sodium [&gt;5], potassium [&gt;0.5], fasting glucose [&gt;0.83], phosphorous [&gt;0.162] millimole/L [mmol/L] above upper limit of normal [ULN] and below lower limit of normal [LLN], non-fasting glucose &gt;5 mmol/L above ULN, &gt;0.56 mmol/L below LLN, creatinine &gt;1.36*ULN, blood urea nitrogen &gt;1.5*ULN, calcium [change of &gt;=0.25 mmol/L], total protein [change of &gt;=20g/L], albumin [change of &gt;=10g/L], uric acid [change of &gt;0.119mmol/L] from baseline and outside normal limits); Liver function tests (alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT] and aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] &gt;2*ULN, total bilirubin &gt;2*ULN, alkaline phosphatase &gt;1.5*ULN, gamma-glutamyl-transpeptidase [GGT] &gt;3*ULN).</description>
        <time_frame>Week 1 up to Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Results of Potential Clinical Importance</title>
          <description>Criteria for PCI laboratory results: hematology (hematocrit [decrease &gt;=5%], hemoglobin [decrease &gt;=20gram/liter {g/L}] from baseline, white blood cells [&lt;3], neutrophils [&lt;1.5], platelet [&lt;100], eosinophils [&gt;0.5] *10^9/L); blood chemistry (sodium [&gt;5], potassium [&gt;0.5], fasting glucose [&gt;0.83], phosphorous [&gt;0.162] millimole/L [mmol/L] above upper limit of normal [ULN] and below lower limit of normal [LLN], non-fasting glucose &gt;5 mmol/L above ULN, &gt;0.56 mmol/L below LLN, creatinine &gt;1.36*ULN, blood urea nitrogen &gt;1.5*ULN, calcium [change of &gt;=0.25 mmol/L], total protein [change of &gt;=20g/L], albumin [change of &gt;=10g/L], uric acid [change of &gt;0.119mmol/L] from baseline and outside normal limits); Liver function tests (alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT] and aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] &gt;2*ULN, total bilirubin &gt;2*ULN, alkaline phosphatase &gt;1.5*ULN, gamma-glutamyl-transpeptidase [GGT] &gt;3*ULN).</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Neurological Examinations</title>
        <description>Neurological examination included the assessment of mental status, cranial nerves, visual fields, sensory, motor, gait, primitive reflexes and tendon reflexes.</description>
        <time_frame>Screening up to Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Neurological Examinations</title>
          <description>Neurological examination included the assessment of mental status, cranial nerves, visual fields, sensory, motor, gait, primitive reflexes and tendon reflexes.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6</title>
        <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6</title>
          <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="2.9"/>
                    <measurement group_id="O2" value="21.0" spread="3.6"/>
                    <measurement group_id="O3" value="21.0" spread="4.6"/>
                    <measurement group_id="O4" value="20.2" spread="2.8"/>
                    <measurement group_id="O5" value="20.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.1"/>
                    <measurement group_id="O2" value="0.0" spread="2.3"/>
                    <measurement group_id="O3" value="-0.3" spread="3.0"/>
                    <measurement group_id="O4" value="-0.2" spread="3.8"/>
                    <measurement group_id="O5" value="-1.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16</title>
        <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16</title>
          <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.9"/>
                    <measurement group_id="O2" value="-0.7" spread="4.1"/>
                    <measurement group_id="O3" value="0.7" spread="2.4"/>
                    <measurement group_id="O4" value="-0.3" spread="2.4"/>
                    <measurement group_id="O5" value="-1.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52</title>
        <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Safety data set included all randomized participants who received at least 1 dose of study medication. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52</title>
          <description>MMSE measures general cognitive functioning: orientation to time (range: 0 to 5) and orientation to place (range: 0 to 5), registration of 3 words (range: 0 to 3), attention and calculation (range: 0 to 5), recall of 3 words (range: 0 to 3), naming (range: 0 to 2), repetition (range: 0 to 1), comprehension (range: 0 to 3), reading (range: 0 to 1), writing (range: 0 to 1) and drawing (range: 0 to 1). Total score is the sum of sub-scores; total score ranges from 0 to 30, higher score indicates better cognitive state.</description>
          <population>Safety data set included all randomized participants who received at least 1 dose of study medication. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.9"/>
                    <measurement group_id="O2" value="-3.8" spread="6.4"/>
                    <measurement group_id="O3" value="-0.7" spread="2.7"/>
                    <measurement group_id="O4" value="-1.2" spread="5.6"/>
                    <measurement group_id="O5" value="-2.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of Bapineuzumab</title>
        <description>Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>Pharmacokinetic (PK) data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of Bapineuzumab</title>
          <description>Participants who received bapineuzumab were reported.</description>
          <population>Pharmacokinetic (PK) data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" spread="0.857"/>
                    <measurement group_id="O2" value="11.1" spread="1.16"/>
                    <measurement group_id="O3" value="21.0" spread="0.968"/>
                    <measurement group_id="O4" value="61.0" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of Bapineuzumab</title>
        <description>Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of Bapineuzumab</title>
          <description>Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" lower_limit="1.08" upper_limit="3.91"/>
                    <measurement group_id="O2" value="1.54" lower_limit="1.00" upper_limit="5.86"/>
                    <measurement group_id="O3" value="1.53" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.71" lower_limit="0.45" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Bapineuzumab</title>
        <description>AUC is a measure of the serum concentration of the drug over time. AUC (0-t) is area under the serum concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of Bapineuzumab</title>
          <description>AUC is a measure of the serum concentration of the drug over time. AUC (0-t) is area under the serum concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>mcg*hour/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1260" spread="254"/>
                    <measurement group_id="O2" value="4264" spread="462"/>
                    <measurement group_id="O3" value="7818" spread="652"/>
                    <measurement group_id="O4" value="15313" spread="8478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Bapineuzumab</title>
        <description>AUC is a measure of the serum concentration of the drug over time. AUC (0 - ∞) is area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Bapineuzumab</title>
          <description>AUC is a measure of the serum concentration of the drug over time. AUC (0 - ∞) is area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>mcg*hour/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279" spread="266"/>
                    <measurement group_id="O2" value="4323" spread="456"/>
                    <measurement group_id="O3" value="7884" spread="640"/>
                    <measurement group_id="O4" value="15405" spread="8438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Clearance (CL) of Bapineuzumab</title>
        <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Clearance (CL) of Bapineuzumab</title>
          <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body. Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>mL/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.88" spread="1.32"/>
                    <measurement group_id="O2" value="7.49" spread="1.71"/>
                    <measurement group_id="O3" value="7.23" spread="1.49"/>
                    <measurement group_id="O4" value="8.84" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss) of Bapineuzumab</title>
        <description>Volume of distribution is defined as the theoretical blood volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss) of Bapineuzumab</title>
          <description>Volume of distribution is defined as the theoretical blood volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state. Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5574" spread="906.5"/>
                    <measurement group_id="O2" value="5947" spread="1406"/>
                    <measurement group_id="O3" value="5827" spread="1611"/>
                    <measurement group_id="O4" value="6879" spread="3132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time of Bapineuzumab</title>
        <description>MRT is average time for which the drug molecules resides in the body, after administration. It is calculated as area under the serum concentration versus time first moment curve from time zero (pre-dose) to extrapolated infinite time (AUMC [0 - ∞]) divided by area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (AUC[0 - ∞]). AUMC (0-∞) is calculated as AUMC(0-inf)= AUMCt + [(t x Ct) / kel] + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method, Ct is the concentration at time t and kel is the terminal phase rate constant. Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time of Bapineuzumab</title>
          <description>MRT is average time for which the drug molecules resides in the body, after administration. It is calculated as area under the serum concentration versus time first moment curve from time zero (pre-dose) to extrapolated infinite time (AUMC [0 - ∞]) divided by area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (AUC[0 - ∞]). AUMC (0-∞) is calculated as AUMC(0-inf)= AUMCt + [(t x Ct) / kel] + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method, Ct is the concentration at time t and kel is the terminal phase rate constant. Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="7.0"/>
                    <measurement group_id="O2" value="33.3" spread="4.4"/>
                    <measurement group_id="O3" value="33.4" spread="5.2"/>
                    <measurement group_id="O4" value="32.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Decay Half-Life (t1/2) of Bapineuzumab</title>
        <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half. Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6 hours post start of infusion on Day 1; Day 2, 3; Week 1, 2, 4, 6, 8, 11, 13, 16, 26, 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Decay Half-Life (t1/2) of Bapineuzumab</title>
          <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half. Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="5.9"/>
                    <measurement group_id="O2" value="26.7" spread="1.8"/>
                    <measurement group_id="O3" value="26.2" spread="3.4"/>
                    <measurement group_id="O4" value="15.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bapineuzumab Concentrations</title>
        <description>Serum bapineuzumab concentration was determined by using a validated enzyme-linked immunosorbent assay (ELISA) method. Participants who received bapineuzumab were reported.</description>
        <time_frame>0 (pre-infusion), 0.5, 1, 1.5, 2, 4, 6, 24, 48, 168, 336, 672, 1008, 1344, 1848, 2184, 2688, 4368, 8736 hours post start of infusion</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration. Here ‘n’ signifies those participants who were evaluable for this measure at the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bapineuzumab Concentrations</title>
          <description>Serum bapineuzumab concentration was determined by using a validated enzyme-linked immunosorbent assay (ELISA) method. Participants who received bapineuzumab were reported.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration. Here ‘n’ signifies those participants who were evaluable for this measure at the specified time point for each arm, respectively.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Hour (n=0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 Hour (n=6,5,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1602" spread="464"/>
                    <measurement group_id="O2" value="5211" spread="1025"/>
                    <measurement group_id="O3" value="8158" spread="332"/>
                    <measurement group_id="O4" value="29206" spread="26241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2970" spread="624"/>
                    <measurement group_id="O2" value="10259" spread="1421"/>
                    <measurement group_id="O3" value="19939" spread="868"/>
                    <measurement group_id="O4" value="48995" spread="41719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3093" spread="696"/>
                    <measurement group_id="O2" value="10861" spread="1398"/>
                    <measurement group_id="O3" value="20423" spread="1559"/>
                    <measurement group_id="O4" value="43798" spread="34612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2854" spread="726"/>
                    <measurement group_id="O2" value="10362" spread="1473"/>
                    <measurement group_id="O3" value="19200" spread="1333"/>
                    <measurement group_id="O4" value="48008" spread="26387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2917" spread="1079"/>
                    <measurement group_id="O2" value="10044" spread="1564"/>
                    <measurement group_id="O3" value="17588" spread="1762"/>
                    <measurement group_id="O4" value="32399" spread="14264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2678" spread="845"/>
                    <measurement group_id="O2" value="9753" spread="1209"/>
                    <measurement group_id="O3" value="18935" spread="1194"/>
                    <measurement group_id="O4" value="34349" spread="14934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2276" spread="665"/>
                    <measurement group_id="O2" value="7774" spread="1249"/>
                    <measurement group_id="O3" value="12983" spread="224"/>
                    <measurement group_id="O4" value="25567" spread="20599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1946" spread="379"/>
                    <measurement group_id="O2" value="6423" spread="774"/>
                    <measurement group_id="O3" value="12179" spread="372"/>
                    <measurement group_id="O4" value="20575" spread="18648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279" spread="225"/>
                    <measurement group_id="O2" value="4431" spread="826"/>
                    <measurement group_id="O3" value="8170" spread="369"/>
                    <measurement group_id="O4" value="15925" spread="10963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="911" spread="271"/>
                    <measurement group_id="O2" value="3441" spread="344"/>
                    <measurement group_id="O3" value="6374" spread="547"/>
                    <measurement group_id="O4" value="12325" spread="5331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>672 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599" spread="80"/>
                    <measurement group_id="O2" value="1940" spread="328"/>
                    <measurement group_id="O3" value="3379" spread="1409"/>
                    <measurement group_id="O4" value="6720" spread="4830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1008 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384" spread="127"/>
                    <measurement group_id="O2" value="1396" spread="326"/>
                    <measurement group_id="O3" value="2295" spread="376"/>
                    <measurement group_id="O4" value="5064" spread="2197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1344 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="76"/>
                    <measurement group_id="O2" value="811" spread="120"/>
                    <measurement group_id="O3" value="1389" spread="318"/>
                    <measurement group_id="O4" value="4440" spread="1755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1848 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="61"/>
                    <measurement group_id="O2" value="519" spread="126"/>
                    <measurement group_id="O3" value="990" spread="312"/>
                    <measurement group_id="O4" value="2172" spread="1289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2184 Hour (n=6,6,4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="49"/>
                    <measurement group_id="O2" value="375" spread="95"/>
                    <measurement group_id="O3" value="796" spread="126"/>
                    <measurement group_id="O4" value="1386" spread="950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2688 Hour (n=6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="41"/>
                    <measurement group_id="O2" value="221" spread="96"/>
                    <measurement group_id="O3" value="468" spread="101"/>
                    <measurement group_id="O4" value="595" spread="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4368 Hour (n=5,5,6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="12"/>
                    <measurement group_id="O2" value="46" spread="20"/>
                    <measurement group_id="O3" value="70" spread="28"/>
                    <measurement group_id="O4" value="25" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8736 Hour (n=0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                    <measurement group_id="O4" value="NA">Concentration was not estimable since no participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Serum Anti-Bapineuzumab Antibody</title>
        <description>Serum anti-bapineuzumab antibody concentration was determined by using a validated ELISA method.</description>
        <time_frame>Baseline (Day 1) up to Week 52</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Serum Anti-Bapineuzumab Antibody</title>
          <description>Serum anti-bapineuzumab antibody concentration was determined by using a validated ELISA method.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Amyloid-beta (x-40) Concentrations</title>
        <description>Amyloid-beta (A-beta) is a peptide fragment of the amyloid precursor protein which is one of the characteristic hallmarks of Alzheimer's disease (AD). Total plasma amyloid-beta (x-40) was determined using a validated ELISA method.</description>
        <time_frame>0 (pre-infusion), 1, 6, 24, 336, 1008, 2184, 2688, 4368, 8736 hours post start of infusion</time_frame>
        <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration. Here ‘n’ signifies those participants who were evaluable for this measure at the specified time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Bapineuzumab 0.15 mg/kg</title>
            <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Bapineuzumab 0.5 mg/kg</title>
            <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Bapineuzumab 1.0 mg/kg</title>
            <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Bapineuzumab 2.0 mg/kg</title>
            <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Amyloid-beta (x-40) Concentrations</title>
          <description>Amyloid-beta (A-beta) is a peptide fragment of the amyloid precursor protein which is one of the characteristic hallmarks of Alzheimer's disease (AD). Total plasma amyloid-beta (x-40) was determined using a validated ELISA method.</description>
          <population>PK data set included all randomized participants who had at least 1 available data of serum bapineuzumab, serum anti-bapineuzumab antibody or plasma amyloid beta concentration. Here ‘n’ signifies those participants who were evaluable for this measure at the specified time point for each arm, respectively.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Hour (n=6,6,6,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309" spread="116"/>
                    <measurement group_id="O2" value="298" spread="91"/>
                    <measurement group_id="O3" value="276" spread="43"/>
                    <measurement group_id="O4" value="339" spread="20"/>
                    <measurement group_id="O5" value="281" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour (n=6,5,5,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1009" spread="369"/>
                    <measurement group_id="O2" value="1050" spread="142"/>
                    <measurement group_id="O3" value="1593" spread="88"/>
                    <measurement group_id="O4" value="1708" spread="247"/>
                    <measurement group_id="O5" value="292" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Hour (n=6,6,6,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1697" spread="871"/>
                    <measurement group_id="O2" value="2664" spread="509"/>
                    <measurement group_id="O3" value="3755" spread="356"/>
                    <measurement group_id="O4" value="3905" spread="656"/>
                    <measurement group_id="O5" value="293" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hour (n=6,6,6,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1474" spread="844"/>
                    <measurement group_id="O2" value="3581" spread="660"/>
                    <measurement group_id="O3" value="5333" spread="426"/>
                    <measurement group_id="O4" value="7405" spread="1630"/>
                    <measurement group_id="O5" value="302" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>336 Hour (n=6,6,6,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784" spread="320"/>
                    <measurement group_id="O2" value="1675" spread="396"/>
                    <measurement group_id="O3" value="3345" spread="485"/>
                    <measurement group_id="O4" value="4325" spread="670"/>
                    <measurement group_id="O5" value="279" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1008 Hour (n=6,6,6,6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543" spread="219"/>
                    <measurement group_id="O2" value="985" spread="328"/>
                    <measurement group_id="O3" value="1566" spread="281"/>
                    <measurement group_id="O4" value="2664" spread="601"/>
                    <measurement group_id="O5" value="287" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2184 Hour (n=6,6,6,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331" spread="119"/>
                    <measurement group_id="O2" value="488" spread="142"/>
                    <measurement group_id="O3" value="668" spread="157"/>
                    <measurement group_id="O4" value="1149" spread="432"/>
                    <measurement group_id="O5" value="278" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2688 Hour (n=6,6,6,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" spread="108"/>
                    <measurement group_id="O2" value="471" spread="114"/>
                    <measurement group_id="O3" value="528" spread="128"/>
                    <measurement group_id="O4" value="803" spread="268"/>
                    <measurement group_id="O5" value="307" spread="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4368 Hour (n=5,6,6,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="86"/>
                    <measurement group_id="O2" value="310" spread="74"/>
                    <measurement group_id="O3" value="351" spread="33"/>
                    <measurement group_id="O4" value="425" spread="68"/>
                    <measurement group_id="O5" value="291" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8736 Hour (n=5,6,6,6,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="107"/>
                    <measurement group_id="O2" value="308" spread="29"/>
                    <measurement group_id="O3" value="342" spread="41"/>
                    <measurement group_id="O4" value="299" spread="22"/>
                    <measurement group_id="O5" value="283" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bapineuzumab 0.15 mg/kg</title>
          <description>Single dose of bapineuzumab (AAB-001) 0.15 milligram per kilogram (mg/kg) intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Bapineuzumab 0.5 mg/kg</title>
          <description>Single dose of bapineuzumab 0.5 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Bapineuzumab 1.0 mg/kg</title>
          <description>Single dose of bapineuzumab 1.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Bapineuzumab 2.0 mg/kg</title>
          <description>Single dose of bapineuzumab 2.0 mg/kg intravenous infusion over 1 hour on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Single dose of placebo matched to bapineuzumab intravenous infusion over 1 hour on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Wyeth</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

